Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M

“We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF and APONVIE,” said Craig Collard, CEO. “In addition to our revenue growth, we are extremely pleased with the continued progress made across all aspects of our business throughout the past year.” Preliminary Q4 and FY25 Updates: Net revenue of approximately $40.5M for the three months ended December 31. ZYNRELEF net revenue of approximately $12.5M for the three months ended December 31. APONVIE net revenue of approximately $3.8M for the three months ended December 31. CINVANTI net revenue of approximately $22.9M for the three months ended December 31. SUSTOL net revenue of approximately $1.3M for the three months ended December 31. Net revenue of approximately $154.9M for FY25. ZYNRELEF delivered the largest quarter-over-quarter revenue increase within the portfolio in Q4.